Back to search results
NCT06914726

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

Enrolling by Invitation
NAAges 18+InterventionalHealth services
HealthPartners Institute
~2,488 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:Patient Centered Clinical Decision Support (PC-CDS)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Resolved care gaps
Measured over 18 months after index date
+2 more outcomes measured

Conditions

Hereditary Breast/Ovarian Cancer (brca1, brca2)
Lynch Syndrome
Genetic Variation
HBOC Syndrome
Hereditary Cancer Syndromes

Explore related trials

BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeLynch SyndromeBRCA1 GeneBRCA2 GeneDNA Mismatch Repair Protein Mlh1EPCAM GeneMSH2 GeneMSH6 GenePMS2 Gene

NCT06914726

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • HealthPartners Medical Group

    Minneapolis, Minnesotano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Patrick J. O'Connor, MD, MPH, MA · PRINCIPAL_INVESTIGATOR · HealthPartners Institute

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Resolved care gaps18 months after index date

    Proportion of patients with a care gap for a specific genetic variant (HBOC: BRCA1, BRCA2; LS: MLH1, MSH2, MSH6, PMS2, or EPCAM) that is resolved within 18 months of index date.

  • Shared decision making12 months after index date

    Patient reports of shared decision making about their genetic risk using the Shared Decision-Making Questionnaire (SDM-Q-9) with total scores ranging from 0-45.

  • Self-efficacy12 months after index date

    Patient reports of self-efficacy in managing cancer-related genetic risk using a modified version of the 12-item Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer) with scores ranging from 12-48.